Validation of the GMFM-88 Scale and of the FAAP-O Scale in Pediatric Patients Affected by Cancer

NCT ID: NCT04862130

Last Updated: 2024-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

217 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-14

Study Completion Date

2023-05-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to validate the Gross Motor Function Measure Scale-88 (GMFM-88) on the Italian pediatric cancer population. The secondary objective is to implement the use of the GMFM-88 in clinical practice by validating a reduced panel of items that will be called the Functional Ability Assessment in Pediatric Oncology (FAAP-O) Scale.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In recent decades, improvements in the treatment of pediatric cancer patients have resulted in increased survival rates. Consequentially, clinicians now pay more attention to the quality of life of these patients, both during and after treatment. Functional abilities have an important role in the quality of life and these skills can be compromised by the tumor itself or by anti-neoplastic treatments. A recent Cochrane review regarding rehabilitation and motor activity in this population has documented the effectiveness of exercise in children with cancer. Furthermore, to improve the rehabilitation care of pediatric cancer patients it is important to broaden the research by structuring multi-center trials, which allow the collection of longitudinal data. Objective, repeatable, specific, and sensitive rehabilitation assessment tools are needed, to define the functional status of the patient and to measure the motor outcomes. The psychometric properties of a measurement are closely linked to the specific population in which the measurement is used. Currently, there are two validated assessment tools for children/adolescents with cancer used to evaluate functional abilities: The Gross Motor Function Scale-Acute Lymphoblastic Leukemia (GMFM-ALL) and the Motor Performance in Pediatric Oncology (MOON). The ladder has the merit of being structured to evaluate the motor skills of children/adolescents affected by various forms of cancer but it also presents some limits. This test does not investigate functional abilities in a rehabilitation optic and it requires the use of specific materials that can reduce its usability in multicenter trials. The GMFM-ALL scale is a modified version of the Gross Motor Function Measure 88 (GMFM-88) Scale. This scale is specific only for children/adolescents with Lymphoblastic Leukemia and it mainly evaluates motor skills that require a high functional level (i.e. jumps, running), possessed neither by younger children nor by those who show major physical impairments or during specific phases of cancer treatment, such as palliative care.

The GMFM-88 scale is a rehabilitation assessment tool that was originally created to investigate functional abilities in children affected by cerebral palsy (CP) and has subsequently been validated for other populations of pediatric patients. It was also used to evaluate functional abilities in some studies conducted on pediatric cancer patients. Some aspects make this tool easily applicable in multicenter studies: it does not require any material to be administered nor a specific certified training to use it and, lastly, it comprises all principal motor skills including the basic ones (i.e. lying and rolling on the ground).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oncology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age between 6 months - 17 years and 11 months
* diagnosis of oncological disease
* being during antineoplastic treatment or up to 1 year off-therapy
* Written informed consent from patient or parents/legal representative, and age-appropriate assent.

Exclusion Criteria

• Patients that are not able and willing to comply with study visits and procedures.
Minimum Eligible Age

6 Months

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Associazione Italiana Ematologia Oncologia Pediatrica

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francesca Rossi, dr

Role: PRINCIPAL_INVESTIGATOR

A.O.U. Città della Salute e della Scienza - OIRM, Turin, Italy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCCS E. Medea La Nostra Famiglia

Bosisio Parini, Lecco, Italy

Site Status

IRCCS E. Medea La Nostra Famiglia

Conegliano, Treviso, Italy

Site Status

Ospedale Papa Giovanni XXIII, UOS Onco-ematologia Pediatrica

Bergamo, , Italy

Site Status

Ospedale Azienda Sanitaria dell'Alto Adige - Comprensorio di Bolzano Servizio di Riabilitazione Fisica

Bolzano, , Italy

Site Status

IRCCS E. Medea La Nostra Famiglia

Brindisi, , Italy

Site Status

AOU Meyer - UP Riabilitazione

Florence, , Italy

Site Status

IRCCS Istituto Giannina Gaslini - U.O. Med Fisica e riabilitazione

Genova, , Italy

Site Status

Fondazione IRCCS Istituto Nazionale dei Tumori - S.C. Cure palliative, Terapia del Dolore e Riabilitazione

Milan, , Italy

Site Status

A.O.U. Città della Salute e della Scienza - OIRM

Torino, , Italy

Site Status

IRCCS Materno Infantile Burlo Garofolo - S.C. Oncoematologia

Trieste, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R; EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014 Jan;15(1):23-34. doi: 10.1016/S1470-2045(13)70546-1. Epub 2013 Dec 5.

Reference Type BACKGROUND
PMID: 24314615 (View on PubMed)

Braam KI, van der Torre P, Takken T, Veening MA, van Dulmen-den Broeder E, Kaspers GJ. Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2016 Mar 31;3(3):CD008796. doi: 10.1002/14651858.CD008796.pub3.

Reference Type BACKGROUND
PMID: 27030386 (View on PubMed)

Byer L, Kline C, Mueller S. Clinical trials in pediatric neuro-oncology: what is missing and how we can improve. CNS Oncol. 2016 Oct;5(4):233-9. doi: 10.2217/cns-2016-0016. Epub 2016 Sep 12.

Reference Type BACKGROUND
PMID: 27616346 (View on PubMed)

Corr AM, Liu W, Bishop M, Pappo A, Srivastava DK, Neel M, Rao B, Wilson T, Ness KK. Feasibility and functional outcomes of children and adolescents undergoing preoperative chemotherapy prior to a limb-sparing procedure or amputation. Rehabil Oncol. 2017 Jan;35(1):38-45.

Reference Type BACKGROUND
PMID: 28948112 (View on PubMed)

Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, Dimitrova N, Jakab Z, Kaatsch P, Lacour B, Mallone S, Marcos-Gragera R, Minicozzi P, Sanchez-Perez MJ, Sant M, Santaquilani M, Stiller C, Tavilla A, Trama A, Visser O, Peris-Bonet R; EUROCARE Working Group. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study. Lancet Oncol. 2014 Jan;15(1):35-47. doi: 10.1016/S1470-2045(13)70548-5. Epub 2013 Dec 5.

Reference Type BACKGROUND
PMID: 24314616 (View on PubMed)

Gemus M, Palisano R, Russell D, Rosenbaum P, Walter SD, Galuppi B, Lane M. Using the gross motor function measure to evaluate motor development in children with Down syndrome. Phys Occup Ther Pediatr. 2001;21(2-3):69-79.

Reference Type BACKGROUND
PMID: 12029855 (View on PubMed)

Gohar SF, Comito M, Price J, Marchese V. Feasibility and parent satisfaction of a physical therapy intervention program for children with acute lymphoblastic leukemia in the first 6 months of medical treatment. Pediatr Blood Cancer. 2011 May;56(5):799-804. doi: 10.1002/pbc.22713. Epub 2011 Jan 16.

Reference Type BACKGROUND
PMID: 21370414 (View on PubMed)

Gotte M, Kesting S, Albrecht C, Worth A, Bos K, Boos J. MOON-test - determination of motor performance in the pediatric oncology. Klin Padiatr. 2013 May;225(3):133-7. doi: 10.1055/s-0033-1343411. Epub 2013 Apr 18.

Reference Type BACKGROUND
PMID: 23599231 (View on PubMed)

Lucia A, Ramirez M, San Juan AF, Fleck SJ, Garcia-Castro J, Madero L. Intrahospital supervised exercise training: a complementary tool in the therapeutic armamentarium against childhood leukemia. Leukemia. 2005 Aug;19(8):1334-7. doi: 10.1038/sj.leu.2403799. No abstract available.

Reference Type BACKGROUND
PMID: 15931268 (View on PubMed)

Ruck-Gibis J, Plotkin H, Hanley J, Wood-Dauphinee S. Reliability of the gross motor function measure for children with osteogenesis imperfecta. Pediatr Phys Ther. 2001 Spring;13(1):10-7.

Reference Type BACKGROUND
PMID: 17053645 (View on PubMed)

Wright MJ, Halton JM, Martin RF, Barr RD. Long-term gross motor performance following treatment for acute lymphoblastic leukemia. Med Pediatr Oncol. 1998 Aug;31(2):86-90. doi: 10.1002/(sici)1096-911x(199808)31:23.0.co;2-v.

Reference Type BACKGROUND
PMID: 9680932 (View on PubMed)

Rossi F, Valle M, Carlucci G, Tofani M, Galeoto G, Berchialla P, Sciannameo V, Clari M, Cardano M, Nota F, Bertin D, Calcagno A, Casalaz R, Cerboneschi M, Cervo M, Cornelli A, Fave MD, Esposito M, Ferrarese M, Imazio P, Lorenzon M, Longo L, Naretto G, Orsini N, Panzeri D, Pellegrini C, Peranzoni M, Picone F, Rabusin M, Trabacca A, Zigrino C, Martinuzzi A, Fagioli F, Ricci F. Development of Functional Abilities Assessment in Paediatric Oncology (FAAP-O) Scale for Children and Adolescents Affected by Cancer. Children (Basel). 2025 Sep 1;12(9):1163. doi: 10.3390/children12091163.

Reference Type DERIVED
PMID: 41007028 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FAAP-O

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.